Replies to post #2442 on InspireMD Inc (NSPR)

[Value_Investor]

NSPR should crash to $0.258048 to be fair considering its recent Over Triple Super-Heavy Huge OS Dilutions --- from 8M shares (when it hit $0.8064) to over 25M shares now! The recent low was $0.8064 anyway!

Sell this Pos Scam at the bids ASAP before it is too late! Then use all the cash proceeds to buy its Mostly Valuable NASDAQ EV peers (such as KXIN: Super-Ridiculous-Low $4,044,292 Market Value with Huge BV/PPS Ratio 12.121 v.s. NSPR has Super-Ridiculous-High $98,970,584 Market Value with Super Tiny BV/PPS Ratio 0.625) to recover all the Huge Losses here! Note, KXIN ever soared to $0.6 in Premarket session just a few months ago!

The Book Value here has already crashed down 75% while the Cash Value here has already crashed down 80% since NSPR hit its recent low $0.8064!

So, sell NSPR ASAP before it creates A Series Of New Lows until it hits $0.258048 in the coming weeks/months...

[TheFinalCD]

The Company’s announcement of FDA approval of the CGuard Prime Carotid Stent System triggers the second of four milestone-driven warrant tranches pursuant to the private placement financing of up to $113.6 million announced in May 2023. Gross proceeds from this warrant tranche are expected to be $17.9M if exercised in full. Proceeds, if any, will be used to support the imminent commercial launch of the CGuard Prime Carotid Stent System in the United States, initiating new regulatory pathways for advanced applications of our CGuard stent platform, and developing new products, while at the same time continuing to develop our business outside of the United States. Warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board members.
https://finviz.com/news/87528/inspiremd-announces-fda-approval-for-cguard-prime-carotid-stent-system-for-the-prevention-of-stroke